Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
15 April 2024 - 7:39PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 15 April 2024 — This company
announcement discloses the data of the transaction(s) made in Novo
Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No.
596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Douglas Langa |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive Vice President |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
ADRs |
|
|
Identification code |
NVO |
|
b) |
Nature of the transaction |
Purchase of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 865.68 |
24.862 ADRs |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
24.862 ADRsDKK 21,522.51 |
|
e) |
Date of the transaction |
2024-04-05 |
|
f) |
Place of the transaction |
New York Stock Exchange |
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Douglas Langa |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive Vice President |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
ADRs |
|
|
Identification code |
NVO |
|
b) |
Nature of the transaction |
Purchase of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 864.99 |
7.904 ADRs |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
7.904 ADRsDKK 6,836.92 |
|
e) |
Date of the transaction |
2024-04-05 |
|
f) |
Place of the transaction |
New York Stock Exchange |
|
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information:
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Company announcement No 30 / 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024